Although the mailbox obligation does not affect the LDC members’ right to refuse to issue or enforce patents on pharmaceutical products until 2016, it does require them to install and maintain administrative procedures that permit the receipt and retention of pending pharmaceutical patent applications for the purpose of later examination (i.e. from 2016 on). That Decision extended the transition period under TRIPS Article 66.1 in 2013. The Decision on the 2013 Extension expressly refers to the LDC transition period “under Article 66.1 of the Agreement”, i.e. the transition period that had to respect the mailbox obligation under Article 70.8(a). This reference has to be understood as carrying over into 2013 the original mailbox obligation under the original transition period.